Found 8 Lupus trials
A listing of Lupus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
XCI Maintenance in Scleroderma and Related Female-Biased Diseases
The research study is being done to understand both why and how scleroderma and related female-biased diseases affect women and men differently. Though we do not know what causes these diseases, we do know that women are much more likely to develop them than men. We are studying how the …
A Phase 2 Multicenter Randomized Double-Blind Placebo-Controlled Parallel Group Trial to Investigate the Efficacy and Safety of Daxdilimab Subcutaneous Injection in Reducing Disease Activity in Adult Participants with Moderate-to-Severe Primary Discoid Lupus Erythematosus
Phase 2
PURPOSE: Phase 2 study to evaluate effect of daxdilimab vs placebo to reduce DLE activity in adults 18-75 yo with DLE. 60 wks 99 pts multiple sites 3 trx grps: placebo; daxdilimab 150 mg; daxdilimab 300 mg. Randomize 1:1:1 sc injections q 4 wks Screening--4 wks; Treatment--48 wks; Follow-Up--8 wks. …
Detection and Characterization of Subclinical Atherosclerotic Plaques in High-Risk Populations of Lupus Erythematosus and Dermatomyositis Patients: A Prospective Single-Center Cohort Study
To determine the burden of subclinical coronary and iliofemoral arterial plaque in 30- to 50-year-old patients with lupus erythematosus (LE) or dermatomyositis (DM) but no clinically evident atherosclerotic cardiovascular disease (ASCVD); and to determine the nature, location, and characteristics of subclinical plaques in these patients. To detect the extent and …
Evaluating Study Drug BIIB059 in Participants with Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)
Phase 2
The research study is being conducted to investigate if the study drug BIIB059 can reduce disease activity and inflammation in people with active Cutaneous Lupus Erythematosus compared to a placebo. Participants will complete the following research procedures: demography and medical history, previous CLE therapy, SARS-CoV-2 (COVID-19) test, chest X-ray, skin …
Studies in Autoimmune Skin Disease
Our goal is to identify markers which can predict response to therapy in patients with dermatomyositis, systemic sclerosis, lupus erythematosus, morphea, eosinophilic fasciitis, and other immune-mediated cutaneous and rheumatic diseases. To collect human tissue from lesional and non-lesional skin, as well as blood, cheek swabs, photographs of biopsy site(s) or …
SIRIUS-LN
This trial seeks to evaluates the efficacy, safety, and tolerability of ianalumab, compared to placebo, in achieving stable complete renal response at week 72 in adults with active lupus nephritis on background SoC therapy.
EnLight
This registry is an observational study designed to assess the utilization and effectiveness of LUPKYNIS in patients with lupus nephritis (LN) in the U.S. This registry is intended to benefit and support interests of patients, clinicians, regulatory bodies, payers, and industry by obtaining longitudinal data on LUPKYNIS.
UPCC 03023: A Phase 1, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Lupus Nephritis
Please see the Protocol, Section 2 (Objectives and Endpoints) Please see the Protocol, Section 2 (Objectives and Endpoints) Please see the Protocol, Section 2 (Objectives and Endpoints)
